NasdaqGS - Nasdaq Real Time Price USD

QuidelOrtho Corporation (QDEL)

39.08 -0.04 (-0.10%)
At close: April 22 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,997,800.00
2,997,800.00
3,266,000.00
1,698,600.00
1,661,668.00
Cost of Revenue
1,503,400.00
1,503,400.00
1,330,000.00
420,300.00
312,813.00
Gross Profit
1,494,400.00
1,494,400.00
1,936,000.00
1,278,300.00
1,348,855.00
Operating Expense
1,241,900.00
1,241,900.00
956,300.00
362,700.00
284,835.00
Operating Income
252,500.00
252,500.00
979,700.00
915,600.00
1,064,020.00
Net Non Operating Interest Income Expense
-176,700.00
-176,700.00
-75,300.00
-400.00
-9,623.00
Other Income Expense
-104,900.00
-104,900.00
-168,500.00
-14,900.00
-14,078.00
Pretax Income
-29,100.00
-29,100.00
735,900.00
900,300.00
1,040,319.00
Tax Provision
-19,000.00
-19,000.00
187,200.00
196,100.00
230,032.00
Net Income Common Stockholders
-10,100.00
-10,100.00
548,700.00
704,200.00
810,287.00
Average Dilution Earnings
--
--
--
--
445.00
Diluted NI Available to Com Stockholders
-10,100.00
-10,100.00
548,700.00
704,200.00
810,732.00
Basic EPS
-0.15
-0.15
9.66
16.74
19.24
Diluted EPS
-0.15
-0.15
9.56
16.43
18.60
Basic Average Shares
66,800.00
66,800.00
56,800.00
42,078.00
42,124.00
Diluted Average Shares
66,800.00
66,800.00
57,400.00
42,874.00
43,591.00
Total Operating Income as Reported
139,100.00
139,100.00
843,700.00
906,000.00
1,060,326.00
Total Expenses
2,745,300.00
2,745,300.00
2,286,300.00
783,000.00
597,648.00
Net Income from Continuing & Discontinued Operation
-10,100.00
-10,100.00
548,700.00
704,200.00
810,287.00
Normalized Income
56,497.00
56,497.00
668,358.40
715,930.00
821,253.76
Interest Income
5,500.00
5,500.00
1,300.00
300.00
--
Interest Expense
178,900.00
178,900.00
74,500.00
300.00
9,623.00
Net Interest Income
-176,700.00
-176,700.00
-75,300.00
-400.00
-9,623.00
EBIT
149,800.00
149,800.00
810,400.00
900,600.00
1,049,942.00
EBITDA
607,000.00
607,000.00
1,094,000.00
953,300.00
1,099,031.00
Reconciled Cost of Revenue
1,251,000.00
1,251,000.00
1,178,900.00
395,000.00
312,813.00
Reconciled Depreciation
457,200.00
457,200.00
283,600.00
52,700.00
49,089.00
Net Income from Continuing Operation Net Minority Interest
-10,100.00
-10,100.00
548,700.00
704,200.00
810,287.00
Total Unusual Items Excluding Goodwill
-84,300.00
-84,300.00
-160,400.00
-15,000.00
-14,078.00
Total Unusual Items
-84,300.00
-84,300.00
-160,400.00
-15,000.00
-14,078.00
Normalized EBITDA
691,300.00
691,300.00
1,254,400.00
968,300.00
1,113,109.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-17,703.00
-17,703.00
-40,741.60
-3,270.00
-3,111.24
12/31/2020 - 2/1/1991

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NARI Inari Medical, Inc.
37.93
-1.71%
 
BIO Bio-Rad Laboratories, Inc.
280.13
+0.14%
 
CNMD CONMED Corporation
72.61
-0.04%
 
IART Integra LifeSciences Holdings Corporation
28.98
+1.05%
 
PODD Insulet Corporation
164.42
-1.10%
 
NVCR NovoCure Limited
11.83
-2.15%
 
INSP Inspire Medical Systems, Inc.
225.22
-1.75%
 
BRKR Bruker Corporation
78.05
+0.37%
 
IRTC iRhythm Technologies, Inc.
113.62
+1.36%
 
PACB Pacific Biosciences of California, Inc.
1.5600
+0.65%